Key result
Elevated CTRP3 is linked to type 2 diabetes and secondary CAD in postmenopausal women.
Why the study?
The roles of CTRP3, CTRP9, and MCP-1 in diabetes mellitus and its vascular complications have not been completely assessed.
Do serum levels of CTRP3, CTRP9, and MCP-1 correlate with the presence of T2DM and CAD in postmenopausal females?
Population
86 postmenopausal females including healthy controls, CAD, T2D ≥5 years, and CAD secondary to T2D
Comparison
Groups: healthy controls vs CAD vs T2D vs CAD secondary to T2D
Design
Cross-sectional study
Authors
Loading...
CTRP3 may support CAD risk assessment in postmenopausal T2D; hypothesis-generating and should not yet change practice.
Cross-Sectional (n=86)
Yes
Do serum levels of CTRP3, CTRP9, and MCP-1 correlate with the presence of T2DM and CAD in postmenopausal females?
p-value: p=<0.05
Serum levels of CTRP3, CTRP9, and MCP-1 are significantly altered in postmenopausal women with T2DM and CAD, suggesting their potential utility as diagnostic or prognostic biomarkers for CAD complications in T2DM.
Ahmed et al. (2018) conducted a cross-sectional in Type 2 Diabetes and Coronary Artery Disease (n=86). Type 2 diabetes and/or coronary artery disease vs. Apparent healthy subjects was evaluated on Serum CTRP3 level (p=<0.05). Serum CTRP3 levels were significantly elevated in postmenopausal females with type 2 diabetes and those with CAD secondary to type 2 diabetes compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: